186 related articles for article (PubMed ID: 2369138)
21. Enhancement of antitumor transplantation resistance in rats by appropriately timed administration of busulfan.
Mizushima Y; Sendo F; Takeichi N; Hosohawa M; Kobayashi H
Cancer Res; 1981 Jul; 41(7):2917-21. PubMed ID: 6454480
[TBL] [Abstract][Full Text] [Related]
22. Augmentation of tumor immunity against syngeneic tumors in mice by beta-carotene.
Tomita Y; Himeno K; Nomoto K; Endo H; Hirohata T
J Natl Cancer Inst; 1987 Apr; 78(4):679-81. PubMed ID: 3470543
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effect of PSK: role of regional lymph nodes and enhancement of concomitant and sinecomitant immunity in the mouse.
Ebina T; Kohya H; Ishikawa K
Jpn J Cancer Res; 1989 Feb; 80(2):158-66. PubMed ID: 2498250
[TBL] [Abstract][Full Text] [Related]
24. [Antitumor effect of human recombinant interferon-alpha A/D in mice(I): Comparison between systemic and lesional treatment of meth-A sarcoma in BALB/c mice].
Nanjo M; Yoshie O; Aso H; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):505-9. PubMed ID: 4004283
[TBL] [Abstract][Full Text] [Related]
25. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
26. Influence of surgical removal and effect of levamisole on cytotoxic T-cell-mediated antitumor immunity in mice.
Gomi K; Morimoto M; Nomoto K
Cancer Res; 1983 Nov; 43(11):5120-5. PubMed ID: 6604572
[TBL] [Abstract][Full Text] [Related]
27. [Differences of antitumor effect of various BRMs by intratumoral administration].
Ebina T; Murata K
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1429-32. PubMed ID: 1530288
[TBL] [Abstract][Full Text] [Related]
28. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
[TBL] [Abstract][Full Text] [Related]
29. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
30. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
31. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
Barker E; Mokyr MB
Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
[TBL] [Abstract][Full Text] [Related]
32. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
Korbelik M; Dougherty GJ
Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
34. Augmentation of specific cell-mediated immune responses to tumor cells in tumor-bearing rats pretreated wih the antileukemia drug busulfan.
Mizushima Y; Sendo F; Miyake T; Kobayashi H
J Natl Cancer Inst; 1981 Apr; 66(4):659-65. PubMed ID: 6939913
[TBL] [Abstract][Full Text] [Related]
35. [Experimental studies on anti-tumor effects of BLC-modified tumor cell vaccine combined with cisplatin].
Zou CH; Tian L; Wei YQ; Zhao X; Kan B; Yang JL; Mao YQ; Wen YJ; Li J; Deng HX
Ai Zheng; 2004 Jan; 23(1):1-7. PubMed ID: 14720366
[TBL] [Abstract][Full Text] [Related]
36. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
Nio Y; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
38. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
[TBL] [Abstract][Full Text] [Related]
39. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity.
Chen XY; Zhang W; Zhang W; Wu S; Bi F; Su YJ; Tan XY; Liu JN; Zhang J
Clin Cancer Res; 2006 Oct; 12(19):5834-40. PubMed ID: 17020991
[TBL] [Abstract][Full Text] [Related]
40. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells.
Shimizu M; Yamamoto A; Nakano H; Matsuzawa A
Cancer Res; 1996 Aug; 56(16):3731-6. PubMed ID: 8706016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
